Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.
• Patients aged ≥ 15 and ≤ 70 years.
• Patients diagnosed with T-ALL/LBL according to 2017 WHO lymphoid malignant disease diagnosis standard.
• Patients with T-ALL/LBL must meet one of the following criteria, A or B.
• A: Refractory T-ALL/LBL disease was defined as follows: Failure to achieve CR at the end of induction.
• B: Relapsed T-ALL/LBL disease was defined as follows: Reappearance of blasts in the blood or bone marrow (\>5%) or in any extramedullary site after a CR.
• ECOG performance status score less than 3.
• Expected survival time \>3 months.
• Patients without serious heart, lung, liver, or kidney disease.
• Ability to understand and voluntarily provide informed consent.